FDA approval. The illumigyn GynescopeTM uses high-resolution and high magnification to digitally capture the cervix, vagina, and external genitalia, allowing for more accurate pap smears. Additionally, the digital data are stored in the cloud and may be accessed remotely for diagnosis, live medical monitoring, and extra consultations, which eliminates the repetition of all the procedures. All Gynescopes are linked to a safe cloud-based system that allows for remote diagnosis and analysis.
As the Gynescope may be used by any certified caregiver or OB/GYN, GP, Midwife, Nurse Practitioner, or Physician Assistant or nurse practitioner, it enables women to be tested and diagnosed even if they reside in distant regions where physicians are not physically available.
Yaron Pinchas, Director of Peramare Pharmaceuticals Nigeria Limited, discussed the cervical cancer risk for Nigerian women. He said, “This agreement is great news for Nigerian women. Nigeria has almost 60 million women that are at risk of developing cervical cancer. Every year 12,000 women are diagnosed, and 8,000 – two-thirds of them – die from cervical cancer. We have to stop this trend, and a critical preventative measure is to introduce widely accessible cervical screening with the help of illumgyn.”
Mr. Ran Poliakine, Founder of illumigyn, spoke about the company’s mission and its services to women’s healthcare. He said, “We established illumigyn to democratize women’s healthcare and to bring advanced gynecological care to women worldwide – including cervical screening”. He added, “We have signed on to the WHO initiative to eradicate cervical cancer within a generation and are proud to be part of driving change across Africa.”
